ASEAN Heart Journal

First online: 

Case Reports

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory

Moo Hyun Kim, Young Seok Lee, Michael S. Lee

04 December 2014

April 2014, 22:7

Case Reports

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

References

1.Appleton DL, Cooke RH, Rao SV, Jovin IS. Anticoagulation in transradial percutaneous coronary intervention. Catheter Cardiovasc Interv 2014;83(2):237–42.

PubMed     CrossRef

 

2.Levine GN, Bate ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: e574–e651.

CrossRef

3.White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 152: 1042–50.

PubMed     CrossRef

 

4.Fifth Organization to Assess Strategies in Acute Ischemic Syndromes investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–76.

CrossRef

 

5.Lincoff AM, Bittl JA, Harrington RA, et al, for the REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853–63.

PubMed    CrossRef

 

6.Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218–30.

PubMed     CrossRef

 

7.Kim MH, Yu LH, Tanaka H, Mitsudo K. Experience with a novel retrograde wiring technique for coronary chronic total occlusion. J Interv Cardiol 2013;26(3):254–8.

PubMed     CrossRef

 

8.Muramatsu T. Current technical and clinical features of the antegrade and retrograde approaches to percutaneous transluminal coronary intervention for chronic total occlusion-2013 version. Syllabus of TOPIC meeting 2013. p179.

 

9.Sharman S, Patel S, Behl A, et al. Extensive Fatal Intracoronary Thrombosis During Percutaneous Coronary Intervention With Bivalirudin. Am J Ther 2013 Jul 25 [Epub ahead of print].

 

10.Stone GW, McLaurin BT, Cox DA, et al, for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–16.

PubMed     CrossRef

11.Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching anti-thrombotic agents for primary angioplasty in acute myocardial infarction. The HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011;57:2309–2316.

PubMed     CrossRef

 

12.Koutouzis M, Lagerqvist B, James S, et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 2011;97 (18):1484–8.

PubMed     CrossRef

13.Langrish JP, Fox KAA. Optimal antithrombotic treatment during primary percutaneous coronary intervention? Heart 2011;97:1459–60.

PubMed     CrossRef

 

14.Shahzad A, Cooper RM, Stables RH. Anthithrombotic therapy in PCI: Why not heprin? Eurointervention 2013;22:423–6.

CrossRef

.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research